MUSTANG BIO, INC. |
Market Closed -
Other stock markets
|
5-day change | 1st Jan Change | ||
| 0.2012 USD | -4.82% |
|
-4.14% | -85.10% |
| 15/05 | Mustang Bio, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2024 | CI |
| 02/05 | Mustang Bio, Inc. announced that it has received $3.3 million in funding | CI |
Presenter SpeechSara Parigian (Attendees)Good afternoon, and welcome to the Mustang Bio KOL ca...
This article is reserved for subscribers To unlock the article, SUBSCRIBE!
Already a customer? Log In
Mustang Bio, Inc. is a clinical-stage biopharmaceutical company focused on translating medical breakthroughs in cell and gene therapies into potential cures for cancers and rare genetic diseases. The Company has partnered with medical institutions to advance the development of chimeric antigen receptor modified T cell (CAR-T) therapies across multiple cancers, as well as lentiviral gene therapies for severe combined immunodeficiency. Its pipeline is focused in three core areas: CAR T therapies for hematologic malignancies, CAR T therapies for solid tumors and gene therapies for rare genetic disorders. It is developing a CAR T therapy for hematologic malignancies in partnership with Fred Hutch targeting CD20 (MB-106). In partnership with St. Jude, its X-linked Severe Combined Immunodeficiency (XSCID) gene therapy programs (MB-117 and MB-217) are being developed under an exclusive license to develop a potentially curative treatment for XSCID, a rare genetic immune system condition.
Calendar
12/08/2024
- Q2 2024 Earnings Release (Projected)
Sell
Buy
Mean consensus
BUY
Number of Analysts
2
Last Close Price
0.2012
USD
Average target price
6
USD
Spread / Average Target
+2,882.11%
EPS Revisions
| 1st Jan change | Capi. | |
|---|---|---|
| -85.10% | 25.05L | |
| +11.91% | 12TCr | |
| +11.60% | 11TCr | |
| -4.68% | 2.43TCr | |
| -0.82% | 2.2TCr | |
| -10.12% | 1.82TCr | |
| -42.12% | 1.64TCr | |
| -17.47% | 1.56TCr | |
| +2.77% | 1.36TCr | |
| +34.58% | 1.23TCr |
- Stock Market
- Equities
- MBIO Stock
- News Mustang Bio, Inc.
- Transcript : Mustang Bio, Inc. - Special Call
